The primary purpose of this explorative study was to develop a therapeutically relevant theory of emotional well-being. The developed theory focuses on coping skills because they are observable, measurable, and teachable. The secondary purpose of this study was to begin researching other important aspects of human nature that may impact emotional well-being. As a foundation to this study, stress and coping theories were reviewed. Contemporary theories concerning coping styles were applied to current conceptions of emotional well-being. The author developed the Well-Being Pilot Test (WBPT) to serve two functions. The WBPT was devised to obtain a useful understanding of the composition of emotional well-being in terms of coping skill divisions. The second function of the WBPT was to begin exploring spiritual, physical, and intellectual health and how they relate to emotional well-being. The WBPT consists of 273 items and was given to 370 people in the United States. The results of this explorative study yielded five coping skill divisions associated with emotional well-being: interpersonal, intrapersonal, stress regulation, emotional stabilization, and problem solving skills. Results of this study are discussed in terms of their usefulness in the therapy session for both, the psychotherapist and the client. The results also indicated that all three of the chosen aspects of human nature (i.e., spiritual, physical, and intellectual health) were significantly related to emotional well-being. Intellectual health was most strongly related to emotional well-being, followed by physical health, and finally, spiritual health. This explorative study, thus, provides pertinent information for the psychotherapist regarding therapeutically relevant conceptualizations of emotional well-being. The information gained from this study will help the psychologist move away from the focus of decreasing emotional sickness to one of encouraging coping skills designed to enhance emotional wellness. Key Words: Emotional well-being, coping skills, stress, wellness, depression, interpersonal, intrapersonal, problem solving, emotional stabilization. / Graduate

Hypotermi, en sänkning av kroppens kärntemperatur under 36°C, är en oönskad men vanlig komplikation under den perioperativa perioden. Det är förenat med en rad negativa konsekvenser som kan orsaka lidande för patienter och innebära ökade vårdkostnader. Svårigheterna med att på ett enkelt och effektivt sätt förhindra hypotermi utgör ett hinder i vården och nya produkter utvecklas därför kontinuerligt. En viktig del i anestesisjuksköterskans arbete är att bevara patientens kroppstemperatur så nära det normala som möjligt. Syftet med föreliggande litteraturstudie var att beskriva olika metoder som är lämpliga för anestesisjuksköterskan att använda för att förhindra hypotermi hos vuxna i det perioperativa förloppet. I de 18 resultatartiklarna testades olika metoder för att bibehålla normal kroppstemperatur: täcka patienten, höjd salstemperatur, värmning med varmluft, elektrisk värmning, värmning av infusionsvätskor, värmning med cirkulerande varmvatten och strålningsvärme. Flera metoder visades effektiva men resultaten var inte entydiga. Inget system visades värma bättre än varmluft. Ytterligare forskning krävs för att fastställa nytta och säkerhet för de övriga aktiva värmesystemen men vissa kan komma att utgöra ett komplement till nuvarande strategier. / Hypothermia, a reduction of the body core temperature below 36°C, is an undesirable but common complication in the perioperative period. It is associated to a series adverse events that can cause discomfort to patients and result in increased health care costs. The difficulties involve a simple and effective way to prevent hypothermia and is an obstacle in the care and new products will develop over time. An important part of nurse anesthetists work is to maintain the patient´s body temperature as close to normal as possible. The aim of the literature study was to describe different methods that is appropriate for the nurse anesthetist to use to prevent hypothermia in adults in the perioperative process. In the results of the 18 articles different forms of methods were tested in order to maintain normal body temperature: cover the patient, raised room temperature, forced air warming, electric heating, fluid warming, warming with circulating hot water and radiant warming. Several methods were shown to be effective but the results were not conclusive. No system was demonstrated to be better than forced air warming. Further research is required to confirm the benefit and safety of the other active warming systems, but some may be in addition to current strategies.

Foram estudadas 20 pacientes na menacme portadoras de leiomioma uterino, sintomáticas, que utilizaram anastrozol na dose 1 mg/dia por três meses consecutivos. Durante o tratamento acompanhou-se o volume do conjunto úteroleiomiomas com ultra-sonografia, no momento inicial e após um mês e três meses do início do uso da medicação. Além disso, foi observada a evolução da sintomatologia relacionada ao leiomioma (hipermenorréia, dismenorréia e metrorragia), presença de sintomas ligados ao hipoestrogenismo e dosagens séricas de FSH, estradiol, colesterol total e frações, triglicérides e glicose. Obtivemos redução média do volume do conjunto útero-leiomiomas de 9,32% até 31%. Houve diminuição significante dos sintomas relacionados ao leiomioma do útero. Não ocorreram sintomas ligados ao hipoestrogenismo. Não se comprovou modificação significante dos demais parâmetros estudados. Concluiu-se que o inibidor da aromatase, o anastrozol, na dosagem utilizada, foi efetivo na redução volumétrica do conjunto útero-leiomiomas, além de proporcionar significativa melhora dos sintomas relacionados a essa doença, sem alterar, no entanto, os valores de FSH, estradiol, colesterol total e frações, triglicérides e glicose. / We studied 20 patients in menacme with leiomyoma in the uterus, referring symptoms, using anastrozol 1 mg per day for three months. During this treatment we monitored the uterus-leiomyoma volume using ultrasound, at the beginning, one month after and three months after the beginning of the use of the medication. We also observed the leiomyoma symptoms evolution, presence of usual symptoms of hipoestrogenism and seric values of FSH, estradiol, cholesterol and its fractions triglycerides and glicemia. We obtained reduction in uterus-leiomyoma volume of 9.32% in average, in maximum 31%. There was significative reduction in symptoms related with leiomyoma. There were not symptoms of hipoestrogenism. We not observed significative modifications in the other studied parameters. This study concluded that the aromatase inhibitor, anastrozol, in this dosage, is effective in uterus-leiomyomas reduction, cause significative reduction of the symptoms related with this illness, without change the seric dosage of FSH, estradiol, total cholesterol and fractions, triglycerides and glicemia.

Foram estudadas 20 pacientes na menacme portadoras de leiomioma uterino, sintomáticas, que utilizaram anastrozol na dose 1 mg/dia por três meses consecutivos. Durante o tratamento acompanhou-se o volume do conjunto úteroleiomiomas com ultra-sonografia, no momento inicial e após um mês e três meses do início do uso da medicação. Além disso, foi observada a evolução da sintomatologia relacionada ao leiomioma (hipermenorréia, dismenorréia e metrorragia), presença de sintomas ligados ao hipoestrogenismo e dosagens séricas de FSH, estradiol, colesterol total e frações, triglicérides e glicose. Obtivemos redução média do volume do conjunto útero-leiomiomas de 9,32% até 31%. Houve diminuição significante dos sintomas relacionados ao leiomioma do útero. Não ocorreram sintomas ligados ao hipoestrogenismo. Não se comprovou modificação significante dos demais parâmetros estudados. Concluiu-se que o inibidor da aromatase, o anastrozol, na dosagem utilizada, foi efetivo na redução volumétrica do conjunto útero-leiomiomas, além de proporcionar significativa melhora dos sintomas relacionados a essa doença, sem alterar, no entanto, os valores de FSH, estradiol, colesterol total e frações, triglicérides e glicose. / We studied 20 patients in menacme with leiomyoma in the uterus, referring symptoms, using anastrozol 1 mg per day for three months. During this treatment we monitored the uterus-leiomyoma volume using ultrasound, at the beginning, one month after and three months after the beginning of the use of the medication. We also observed the leiomyoma symptoms evolution, presence of usual symptoms of hipoestrogenism and seric values of FSH, estradiol, cholesterol and its fractions triglycerides and glicemia. We obtained reduction in uterus-leiomyoma volume of 9.32% in average, in maximum 31%. There was significative reduction in symptoms related with leiomyoma. There were not symptoms of hipoestrogenism. We not observed significative modifications in the other studied parameters. This study concluded that the aromatase inhibitor, anastrozol, in this dosage, is effective in uterus-leiomyomas reduction, cause significative reduction of the symptoms related with this illness, without change the seric dosage of FSH, estradiol, total cholesterol and fractions, triglycerides and glicemia.